- (PLX AI) - Genmab shares rose 2.8% in morning trading after Danske upgraded the stock to buy, saying the biotech company's pipeline has multiple potential catalysts this year.
- • Darzalex arbitration with Johnson & Johnson is an overhang, but the analysts expect a positive resolution in the near term
- • Darzalex sales growth should continue strongly: Danske
- • Price target DKK 3,100
© 2022 PLX AI
